With regards to the favorable effect of CTRP3 on the mechanism of T2DM development and its complications such as insulin resistance, inflammation, and endothelial dysfunction, reduced levels of CTRP3 could be a factor that exacerbates pathogenic conditions in patients with T2DM. This evidence concerns the gene C1QTNF3 and endothelial dysfunction.